JAK2 (V617F) Positive Latent Myeloproliferative Neoplasm Presenting with Splanchnic Vein Thrombosis

Case Report
  • 159 Downloads

Abstract

Myeloproliferative neoplasms (MPNs) are chronic clonal hematopoietic stem cell disorders characterized by proliferation of one or more of the granulocytic, red cell or platelet lineages in the bone marrow, with fairly normal maturation, resulting in increase in the leukocyte, erythrocytes and platelets in the blood. They also represent a common cause of splanchnic vein thrombosis (SVT). Herein, we describe a case of SVT as a presenting symptom of latent MPN. The patient has had normal complete blood counts since presentation. 3 ½ years later, she was found to have JAK2 (V617F) mutation and bone marrow biopsy was consistent with MPN. Five years later, her platelet count started to rise. In patients with a first episode of SVT, thrombophilia workup including JAK2 (V617F) mutation is warranted. Anticoagulation with heparin and warfarin is the treatment of choice for SVT.

Notes

Conflict of interest

None.

References

  1. 1.
    Vardiman JW, Thiele J, Arber DA et al (2009) The 2008 revision of World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114:937–951PubMedCrossRefGoogle Scholar
  2. 2.
    Tefferi A (2007) JAK2 mutations in polycythemia vera –molecular mechanisms and clinical applications. N Engl J Med 356:444–446PubMedCrossRefGoogle Scholar
  3. 3.
    Goldman J (2005) A unifying mutation in chronic myeloproliferative disorders. N Engl J Med 352:1744–11746PubMedCrossRefGoogle Scholar
  4. 4.
    Baxter EJ, Scott LM, Campbell PJ et al (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054–1061PubMedCrossRefGoogle Scholar
  5. 5.
    James C, Ugo V, LE Coudeidc JP et al (2005) A unique JAK2 mutation leading to constitutive signaling causes polycythemia vera. Nature 434:1144–1148PubMedCrossRefGoogle Scholar
  6. 6.
    Kralovics R, Passamonti F, Buser AS et al (2005) A gain–of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779–1790PubMedCrossRefGoogle Scholar
  7. 7.
    Levine RL, Wadleigh M, Cools J et al (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with fibrosis. Cancer Cell 7:1387–1397CrossRefGoogle Scholar
  8. 8.
    Zhao R, Xing S, Li Z et al (2005) Identification of an acquired JAK2 mutation in polycythemia vera. J Bio Chem 280:22788–22792CrossRefGoogle Scholar
  9. 9.
    Tefferi A (2006) Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era. Hematology 240-245Google Scholar
  10. 10.
    Kniffin WD, Baron JA, Barret J et al (1994) The epidemiology of diagnosed pulmonary embolism and deep vein thrombosis in the elderly. Arch Intern Med 154:861–866PubMedCrossRefGoogle Scholar
  11. 11.
    Kiladjian JJ, Cervantes F, Leebeek WG, Marzac C, Cassinat B et al (2008) Impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report of 241 cases. Blood 111:4922–4929PubMedCrossRefGoogle Scholar
  12. 12.
    De Stephano V, Teophili L, Leone G et al (1997) Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis. Semin Thromb Hemost 23:411–418CrossRefGoogle Scholar
  13. 13.
    Boissinot M, Lippert E, Girodon F et al (2006) Latent myeloproliferative disorder revealed by the JAK2-V617F mutation and endogenous megakaryocyte colonies in patients with splanchnic vein thrombosis. Blood 108(9):3223–3224PubMedCrossRefGoogle Scholar
  14. 14.
    Primignani M, Barosi G, Bergamaschi G et al (2006) Role of JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology 44(6):1528–1534PubMedCrossRefGoogle Scholar
  15. 15.
    Patel RK, Lea NC, Heneghan MA et al (2006) Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology 130:2031–2038PubMedCrossRefGoogle Scholar
  16. 16.
    De Stephano V, Fiorini A, Rossi E, Za T et al (2007) Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt myeloproliferative disorder. J Thromb Hemost 5:708–714CrossRefGoogle Scholar
  17. 17.
    De Stefano V, Fiorini A, Rossi E et al (2007) High prevalence of the JAK2 V617F mutation in patients with extrahepatic portal vein thrombosis. Hepatology 45:831–833PubMedCrossRefGoogle Scholar
  18. 18.
    Bayraktar Y, Harmanci O, Buyukasik Y et al (2008) JAK2V617F mutation in patients with portal vein thrombosis. Dig Dis Sci 53:2778–2783PubMedCrossRefGoogle Scholar
  19. 19.
    Goulding C, Uttenthal B, Foroni L et al (2008) The JAK2 (V617F) tyrosine kinase mutation identifies clinically latent myeloproliferative disorders in patients presenting with hepatic or portal vein thrombosis. Int J Lab Hematol 30:415–419PubMedCrossRefGoogle Scholar
  20. 20.
    Regina S, Herault O, D’Alteroche L et al (2007) JAK2 V617F is specifically associated with idiopathic splanchnic vein thrombosis. J Thromb Haemost 5:859–861PubMedCrossRefGoogle Scholar
  21. 21.
    Colaizzo D, Amitrano L, Tiscia GL et al (2007) The JAK2V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost 5:55–61PubMedCrossRefGoogle Scholar
  22. 22.
    Colaizzo D, Amitrano L, Iannaccone L et al (2008) Occurrence of the JAK2 V617F mutation in the Budd-Chiari syndrome. Blood Coagul Fibrinolysis 19:459–462PubMedCrossRefGoogle Scholar
  23. 23.
    Tefferi A, Lasho TL, Schwager SM et al (2006) The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer 106:631–635PubMedCrossRefGoogle Scholar
  24. 24.
    Tondeur S, Boutruche S, Biron-Andreani C et al (2009) Prevalence of the JAK2 V617 mutation associated with splanch vein thrombosis. A 10-year retrospective study. Thromb Haemost 101:787–789PubMedGoogle Scholar
  25. 25.
    Kubota Y, Tanaka T, Ohnishi H et al (2004) Constitutively activated phosphotidylinositol 3-kinase primes platelets from patients with chronic myelogeneous leukemia for thrombopoietin-induced aggregation. Leukemia 18:1127–1137PubMedCrossRefGoogle Scholar
  26. 26.
    Falanga A, Marchetti M, Vignoli A et al (2007) V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules. Exp Hematol 35:702–711PubMedCrossRefGoogle Scholar
  27. 27.
    Robertson B, Urquhart C, Ford I et al (2007) Platelet and coagulation activation markers in myeloproliferative diseases: relationships with JAK2 V617F status, clonality and antiphospholipid antibodies. J Thromb Hemost 5:1679–1685CrossRefGoogle Scholar
  28. 28.
    Wautier MP, El Nemer W, Gane P et al (2007) Increased adhesion to endothelial cells of erythrocytes from patients with polycythemia vera is mediated by laminin alpha5 chain and Lu/BCAM. Blood 110:894–901PubMedCrossRefGoogle Scholar
  29. 29.
    Cheung B, Radia D, Pantelidis P et al (2006) The presence of the JAK2 V617F mutation is associated with a higher hemoglobin and increased risk of thrombosis in essential thrombocythemia. Br J Haematol 132:244–245PubMedCrossRefGoogle Scholar
  30. 30.
    Smallberg JH, Murad SD, Braakman E et al (2006) Myeloproliferative disease in the pathogenesis and survival of Budd-Chiari syndrome. Haematologica 91:1712–1713Google Scholar
  31. 31.
    Landolfi R, Di Gennaro L, Barbui T et al (2007) Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 109:2446–2452PubMedCrossRefGoogle Scholar
  32. 32.
    McMahon C, Abu-Elmagh K, Bontempo FA et al (2007) JAK2 V617F mutation in patients with catastrophic intra-abdominal thromboses. Am J Clin Pathol 127:736–743PubMedCrossRefGoogle Scholar
  33. 33.
    Dentali F, Squizzato A, Brivio L et al (2009) JAK2V617F mutation for early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. Blood 113(22):5617–5623PubMedCrossRefGoogle Scholar

Copyright information

© Indian Society of Haematology & Transfusion Medicine 2012

Authors and Affiliations

  1. 1.St Elizabeth’s Medical Center, Tufts University School of MedicineBostonUSA
  2. 2.University of Texas M. D. Anderson Cancer Center, Section of Thrombosis & Benign HematologyHoustonUSA
  3. 3.University of Virginia School of MedicineCharlottesvilleUSA

Personalised recommendations